Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of -810.41% is 842% below its 5-year average of -86.05%, near the low end of its 5-year range (-810.41%–-38.48%).
As of the fiscal period ended Tuesday, June 30, 2026. 142.96% below its 12-month average of -333.56%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): -810.41%.
RETURN ON EQUITY (ROE)
-810.41%
RETURN ON EQUITY (ROE) AVG TTM
-333.56%
RETURN ON EQUITY (ROE) AVG 3Y
-105.05%
RETURN ON EQUITY (ROE) AVG 5Y
-86.05%
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
-142.96%
CURRENT VS 3Y AVG
-671.47%
CURRENT VS 5Y AVG
-841.79%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-41.78%
median of 742 covered companies
CURRENT VS SECTOR MEDIAN
-1839.48%
vs the sector median at left
Passage Bio, Inc.
Market Cap
$12.95M
Return on Equity (ROE)
-810.41%
TTM Avg
-333.56%
3Y Avg
-105.05%
5Y Avg
-86.05%
Market Cap
$13.14M
Return on Equity (ROE)
-101.66%
TTM Avg
-140.38%
3Y Avg
-131.64%
5Y Avg
-101.94%
Market Cap
$12.69M
Return on Equity (ROE)
-85.82%
TTM Avg
-222.53%
3Y Avg
-140.00%
5Y Avg
-73.12%
Market Cap
$12.66M
Return on Equity (ROE)
N/A
TTM Avg
-162.71%
3Y Avg
-135.96%
5Y Avg
-98.83%
Market Cap
$12.57M
Return on Equity (ROE)
N/A
TTM Avg
-201.97%
3Y Avg
-21.23%
5Y Avg
365.72%
Market Cap
$13.33M
Return on Equity (ROE)
-39.76%
TTM Avg
-59.76%
3Y Avg
-51.18%
5Y Avg
-40.48%
Market Cap
$12.54M
Return on Equity (ROE)
-74.73%
TTM Avg
-265.78%
3Y Avg
-138.63%
5Y Avg
-109.18%
Market Cap
$12.54M
Return on Equity (ROE)
N/A
TTM Avg
-306.31%
3Y Avg
-229.99%
5Y Avg
-161.76%
Market Cap
$13.50M
Return on Equity (ROE)
-69.47%
TTM Avg
-55.64%
3Y Avg
-44.95%
5Y Avg
-41.56%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Passage Bio, Inc. (PASG) | $12.95M | -810.41% | -333.56% | -105.05% | -86.05% |
| IN8bio, Inc. (INAB)vs › | $13.14M | -101.66% | -140.38% | -131.64% | -101.94% |
| Bullfrog AI Holdings, Inc. Common Stock (BFRG)vs › | $12.69M | -85.82% | -222.53% | -140.00% | -73.12% |
| Cytosorbents Corporation (CTSO)vs › | $12.66M | N/A | -162.71% | -135.96% | -98.83% |
| Dare Bioscience, Inc. (DARE)vs › | $12.57M | N/A | -201.97% | -21.23% | 365.72% |
| Optimi Health Corp. (OPTH)vs › | $13.33M | -39.76% | -59.76% | -51.18% | -40.48% |
| Cellectar Biosciences, Inc. (CLRB)vs › | $12.54M | -74.73% | -265.78% | -138.63% | -109.18% |
| Tempest Therapeutics, Inc. (TPST)vs › | $12.54M | N/A | -306.31% | -229.99% | -161.76% |
| Citius Pharmaceuticals, Inc. (CTXR)vs › | $13.50M | -69.47% | -55.64% | -44.95% | -41.56% |
| Lantern Pharma Inc. (LTRN)vs › | $12.31M | N/A | -180.04% | -6461.50% | -4315.55% |
ROE
-810.4%
ROA
-143.4%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | -810.41% |
| 2026-03-31 | -320.59% |
| 2025-12-31 | -242.72% |
| 2025-09-30 | -145.45% |
| 2025-06-30 | -148.61% |
| 2025-03-31 | -135.87% |
| 2024-12-31 | -105.72% |
| 2024-09-30 | -94.61% |
| 2024-06-30 | -84.55% |
| 2024-03-31 | -80.50% |
| 2023-12-31 | -91.71% |
| 2023-09-30 | -88.99% |
| 2023-06-30 | -74.44% |
| 2023-03-31 | -74.93% |
| 2022-12-31 | -67.60% |
| 2022-09-30 | -71.40% |
| 2022-06-30 | -72.74% |
| 2022-03-31 | -67.30% |
| 2021-12-31 | -58.18% |
| 2021-09-30 | -47.81% |
| 2021-06-30 | -38.48% |
| 2021-03-31 | -30.24% |
| 2020-12-31 | -36.83% |
| 2020-09-30 | -25.51% |
| 2020-06-30 | -19.07% |
| 2020-03-31 | -14.37% |
| 2019-12-31 | -26.17% |
| 2019-09-30 | -20.54% |
